INTERCEPT is not approved for sale in the United States and certain other countries.

  • Replaced gamma irradiation for prevention of TA-GvHD

  • Provides a proactive protection against bacteria, eliminating the need for bacterial detection

  • Provides a proactive protection against emerging pathogens

Collection Platform:
Amicus (Fenwal), Trima Accel (CaridianBCT)

Platelet Suspension Medium:
PAS - InterSol (Fenwal)

INTERCEPT Disposable Set:
INT2103B

Separation Platform:
Manual 5 (Buffy Coats)

Platelet Suspension Medium:
PAS - InterSol (Fenwal)

INTERCEPT Disposable Set:
INT2203B

 

Customer Profile: St. Olavs Hospital inTrondheim, Norway

Date of INTERCEPT Implementation
2003: Apheresis & Buffy Coat Platelets

Annual Collections

• 17,000 whole blood donations
• 1,400 apheresis donations


Annual INTERCEPT Production
• 2,300 units of platelet concentrates

www.stolav.no


Center Profile
Helseforetaket St. Olavs Hospital in Trondheim, Norway serves the community of Sør-Trøndelag which has a population of approximately 270,000 people. The hospital blood center collects and processes blood components to support the transfusion needs of patients within their 880 bed facility.

As a hospital-based blood center, adopting a single technology that addresses multiple blood safety concerns was a critical consideration for the hospital. As a result, St. Olavs Hospital was an early adopter of the INTERCEPT Blood System for platelets in 2003; they INTERCEPT-treat 100% of their buffy coat and apheresis platelet collections. The blood center operates 3 shifts per day.

Production Lab
INTERCEPT processing at St. Olavs Hospital Blood Bank requires less than 20m2. The blood center takes advantage of the stackable design of the INTERCEPT Illuminator to reduce the overall space requirements for treatment. The illuminators include a tray-tilt feature which facilitates loading and unloading of products into the upper illuminator, as well as routine cleaning. Locating the INTERCEPT treatment room proximate to the platelet preparation room maximizes the center’s efficiency.

INTERCEPT Workflow
St. Olavs Hospital Blood Bank treats both apheresis and buffy coat platelets. As depicted below, collections generally occur in the morning. Thanks to the flexibility of the INTEREPT process, the very first apheresis collections of the day are INTERCEPT-treated and released the same day as collection. Platelets prepared via the buffy coat method are pooled and INTERCEPT-treated on Day 1.
 

INTERCEPT Quality Control Results
Since 2003, St. Olavs Hospital Blood Bank pathogen inactivates 100% of their apheresis and buffy-coat derived platelet units with the INTERCEPT Blood System. Quality Control measurements are performed on a routine basis to monitor fulfillment of the end product's characteristics with the center requirements.


Table 1: St. Olavs Hospital Validation Results for
INTERCEPT Platelets (Apheresis)a
Parameter
INTERCEPT Platelets
Average       Std. Dev
N
Volume (mL)
271
18
167
Platelet Count (x1011 plt/unit)
2.8
0.5
165
pH (day 8)
6.8
0.1
17
a. Volume and platelet counts are post PI.


Table 2: St. Olavs Hospital Validation Results for
INTERCEPT Platelets (Buffy Coat)a
Parameter
INTERCEPT Platelets
Average       Std. Dev
N
Volume (mL)
346
12
194
Platelet Count (x1011 plt/unit)
2.8
0.3
189
pH (day 8)
6.7
0.1
54
a. Volume and platelet counts are post PI.
 


 

 

Untitled Document